Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Rheumatoid Arthritis

Free Subscription Articles published in Clin Exp Rheumatol Retrieve available abstracts of 177 articles: HTML format

Single Articles

January 2026
1. BAGCHI A, Ghosh P, Ghosh A, Chatterjee M, et al
   Do intrasynovial T lymphocytes facilitate disease progression in patients with rheumatoid arthritis?
   Clin Exp Rheumatol. 2026 Jan 28. doi: 10.55563.
   PubMed     Abstract available
   
   
   
2. CIMMINO G, Mauro D, Morello M, Titolo G, et al
   Tofacitinib attenuates IL-6-mediated endothelial tissue factor induction in vitro without affecting platelet aggregation in vivo: mechanistic insights into cardiovascular risk in rheumatoid arthritis.
   Clin Exp Rheumatol. 2026 Jan 5. doi: 10.55563.
   PubMed     Abstract available
   
   
   
3. SUZUKI K, Akiyama M, Shimanuki K, Kaneko Y, et al
   Impact of concomitant methotrexate on JAK inhibitors in rheumatoid arthritis-associated interstitial lung disease: a retrospective single-centre study from the KEIO-RA cohort.
   Clin Exp Rheumatol. 2026 Jan 5. doi: 10.55563.
   PubMed     Abstract available
   
   
   December 2025
4. BAETEN D, Kohsaka H, Miura D
   Targeting fibroblast-like synoviocytes with CDK4/6 inhibitors as a novel, non-immunosuppressive treatment strategy for rheumatoid arthritis.
   Clin Exp Rheumatol. 2025 Dec 2. doi: 10.55563.
   PubMed     Abstract available
   
   
   
5. BRITO-ZERON P, Flores-Chavez A, Horvath IF, Priori R, et al
   Sex disparities in the phenotype at diagnosis of Sjogren's disease: artificial intelligence-driven characterisation in 17,416 patients.
   Clin Exp Rheumatol. 2025;43:2133-2141.
   PubMed     Abstract available
   
   
   
6. DELGADO L, Flores-Chavez A, Szanto A, Priori R, et al
   Immunological signatures in patients with Sjogren's disease: association with systemic disease activity at diagnosis.
   Clin Exp Rheumatol. 2025;43:2124-2132.
   PubMed     Abstract available
   
   
   
7. JIANG X, Liang X, Hong Y, Hua C, et al
   Machine learning-based identification of pyroptosis-related genes as biomarkers and targets in primary Sjogren's syndrome.
   Clin Exp Rheumatol. 2025;43:2172-2187.
   PubMed     Abstract available
   
   
   
8. CHENG CF, Chen TC, Hsieh MS, Lan TY, et al
   Length-based adequacy thresholds for submandibular gland core needle biopsy in suspected Sjogren's disease: two-phase study.
   Clin Exp Rheumatol. 2025;43:2188-2196.
   PubMed     Abstract available
   
   
   
9. ATZENI F, Curro ML, Dal Pozzolo R, Cafaro G, et al
   Clinical and serological differences of an Italian Sjogren's disease cohort according to three geographic macro-area localisations.
   Clin Exp Rheumatol. 2025;43:2036-2044.
   PubMed     Abstract available
   
   
   
10. STUCIN N, Perdan Pirkmajer K, Hocevar A, Cucnik S, et al
    Diagnostic potential of soluble and membrane-bound inducible T-cell co-stimulator in Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2152-2160.
    PubMed     Abstract available
    
    
    
11. WANG J, Mo L, Tang X, Feng X, et al
    Salivary cystatin D is a candidate non-invasive biomarker for primary Sjogren's syndrome diagnosis and salivary gland injury.
    Clin Exp Rheumatol. 2025;43:2053-2059.
    PubMed     Abstract available
    
    
    
12. FONZETTI S, La Rocca G, Fulvio G, Dei B, et al
    Clinical impact of anti-SSA antigenic specificity on disease activity and patient-reported outcomes in primary Sjogren's disease: a real-life cohort study.
    Clin Exp Rheumatol. 2025;43:2209-2216.
    PubMed     Abstract available
    
    
    
13. DEI B, La Rocca G, Dal Pozzolo R, Fulvio G, et al
    Damage accrual in Sjogren's disease. Prevalence, risk factors and impact on quality of life: a systematic review.
    Clin Exp Rheumatol. 2025;43:2217-2223.
    PubMed     Abstract available
    
    
    
14. ZABOTTI A, Manfre V, Nano A, Giovannini I, et al
    Correlation between colour Doppler activity and parenchymal alterations in salivary glands of patients with primary Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2202-2208.
    PubMed     Abstract available
    
    
    
15. PANAGOPOULOS PK, Chatzis LG, Malagari K, Goules AV, et al
    Treatment and follow-up of patients with Sjogren's disease associated interstitial lung disease: a case series.
    Clin Exp Rheumatol. 2025;43:2197-2201.
    PubMed     Abstract available
    
    
    
16. CHATZIS LG, Pontarini E, Fulvio G, La Rocca G, et al
    Evolving mechanisms in the pathogenesis of Sjogren's disease: one year in review 2025.
    Clin Exp Rheumatol. 2025;43:2020-2028.
    PubMed     Abstract available
    
    
    
17. LEMOS LOPES ML, Fernandes Moca Trevisani V, Cantali DU, Coradin R, et al
    Two-dimentional shear wave elastography as an alternative method of ultrasound for major salivary gland evaluation in Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2142-2151.
    PubMed     Abstract available
    
    
    
18. YANG L, Tong Y, Jin Y, Wang X, et al
    An accurate predictive model for depressive symptoms in patients with primary Sjogren's disease based on machine learning algorithms.
    Clin Exp Rheumatol. 2025;43:2161-2171.
    PubMed     Abstract available
    
    
    
19. SULUDERE MA, Sluijpers NRF, Arends S, Stel AJ, et al
    Estimating the reliability of salivary gland ultrasound scoring in Sjogren's disease: the outcome of an international training workshop.
    Clin Exp Rheumatol. 2025;43:2102-2110.
    PubMed     Abstract available
    
    
    
20. LI R, Jia Y, Wu X, Wang M, et al
    Dysregulated plasmacytoid dendritic cells in primary Sjogren's syndrome: normal functionality but decreased quantities.
    Clin Exp Rheumatol. 2025;43:2069-2081.
    PubMed     Abstract available
    
    
    
21. CHATZIS LG, Manfre V, Colangelo A, Delli K, et al
    Clinical manifestations, imaging and treatment of Sjogren's disease: one year in review 2025.
    Clin Exp Rheumatol. 2025;43:2007-2019.
    PubMed     Abstract available
    
    
    
22. ARENDS S, Bouillot C
    Research evidence and patient perspective on the impact of lifestyle factors in patients with Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2029-2035.
    PubMed     Abstract available
    
    
    
23. WANG Q, He L, Han Y
    Uncovering CD248, MMP28, and SLC16A10 in Sjogren's disease: a machine learning-driven SHAP approach for CD4+ T cell-associated biomarker discovery.
    Clin Exp Rheumatol. 2025;43:2111-2123.
    PubMed     Abstract available
    
    
    
24. LIU W, Guo Z, Wang X, Lu N, et al
    Quality of life in patients with Sjogren's disease: a bibliometric analysis.
    Clin Exp Rheumatol. 2025;43:2089-2101.
    PubMed     Abstract available
    
    
    
25. WANG ZM, Yang YS, Qi X, Zhang Y, et al
    Comparison and clinical analysis of tissue-specific autoantibody levels in primary Sjogren's disease and other connective tissue diseases.
    Clin Exp Rheumatol. 2025;43:2060-2068.
    PubMed     Abstract available
    
    
    
26. CRUZ-BAUTISTA I, Gomez-Velasco D, Garcia-Torralba A, Aguilar-Salinas CA, et al
    Obesity in primary Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2082-2088.
    PubMed     Abstract available
    
    
    
27. FRANCO AS, Murai IH, Yang TH, Bonoldi VLN, et al
    Association of visceral adipose tissue with inflammation and functional impairment in women with Sjogren's disease.
    Clin Exp Rheumatol. 2025;43:2045-2052.
    PubMed     Abstract available
    
    
    November 2025
28. KIDOGUCHI G, Ishitoku M, Oka N, Kobayashi H, et al
    Patient clustering by serum inflammatory mediators stratifies early disease-modifying antirheumatic drug-naive rheumatoid arthritis and reveals distinct pathobiological signatures: a prospective observational cohort.
    Clin Exp Rheumatol. 2025 Nov 12. doi: 10.55563.
    PubMed     Abstract available
    
    
    
29. MOVAHEDI M, Kuriya B, Cesta A, Li X, et al
    Treatment sequences and lines of therapy in rheumatoid arthritis: a real-world evaluation of retention and effectiveness.
    Clin Exp Rheumatol. 2025 Nov 12. doi: 10.55563.
    PubMed     Abstract available
    
    
    
30. BJORNSSON AH, Thrastardottir T, Gudbjornsson B, Love TJ, et al
    Temporal trends in overall infection incidence in patients with inflammatory arthritides treated with tumour necrosis factor inhibitors: a nationwide cohort study.
    Clin Exp Rheumatol. 2025;43:1879-1887.
    PubMed     Abstract available
    
    
    October 2025
31. SHEN M, You C
    Exploring the comorbidity mechanism of rheumatoid arthritis and systemic lupus erythematosus through transcriptomics and conducting experimental validation.
    Clin Exp Rheumatol. 2025 Oct 29. doi: 10.55563.
    PubMed     Abstract available
    
    
    
32. LV H, Li Y, Wang R, Gao Y, et al
    MXRA5 is identified and validated as a key gene related to epithelial-mesenchymal transition in rheumatoid arthritis fibroblast-like synoviocytes.
    Clin Exp Rheumatol. 2025 Oct 16. doi: 10.55563.
    PubMed     Abstract available
    
    
    
33. WEMAN L, Salo H, Rantalaiho V, Huhtakangas J, et al
    Does different administration method of methotrexate matter in early rheumatoid arthritis? An exploratory register-based study.
    Clin Exp Rheumatol. 2025 Oct 16. doi: 10.55563.
    PubMed     Abstract available
    
    
    September 2025
34. HOSOKAWA Y, Yoshida Y, Tamai H, Hirata S, et al
    Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study.
    Clin Exp Rheumatol. 2025 Sep 19. doi: 10.55563.
    PubMed     Abstract available
    
    
    
35. YANG W, Chen J, Wang X
    Rheumatoid arthritis: emerging insights into molecular mechanisms and targeted immunotherapy.
    Clin Exp Rheumatol. 2025 Sep 2. doi: 10.55563.
    PubMed     Abstract available
    
    
    
36. ZHANG W, Zhuang D, Lu H, Lv Z, et al
    Predictions of rheumatoid arthritis burden in 204 countries and territories by 2044: based on the Global Burden of Disease Study 2021.
    Clin Exp Rheumatol. 2025 Sep 2. doi: 10.55563.
    PubMed     Abstract available
    
    
    
37. NOTO G, Salvetti F, Demaj A, Altieri P, et al
    Pathogenesis of rheumatoid arthritis: one year in review 2025.
    Clin Exp Rheumatol. 2025;43:1533-1540.
    PubMed     Abstract available
    
    
    
38. ISHII A, Nakayamada S, Ohkubo N, Miyazaki Y, et al
    Reduction of non-classical monocytes that suppress interferon-alpha in patients with systemic lupus erythematosus.
    Clin Exp Rheumatol. 2025;43:1568-1576.
    PubMed     Abstract available
    
    
    August 2025
39. MOVAHEDI M, Li X, Cesta A, Bombardier C, et al
    COVID-19 in rheumatoid arthritis: prevalence, hospital admission, and risk of all-cause mortality before and after COVID-19 pandemic.
    Clin Exp Rheumatol. 2025 Aug 29. doi: 10.55563.
    PubMed     Abstract available
    
    
    July 2025
40. MOLE EN, Tarassi AE, Tsirogianni AG, Athanasiades TE, et al
    Interaction of HLA-DRB1 shared epitope and smoking on the development of anti-citrullinated protein antibody positive rheumatoid arthritis in Greek patients.
    Clin Exp Rheumatol. 2025 Jul 25. doi: 10.55563.
    PubMed     Abstract available
    
    
    
41. HU W, Xu Y
    Bibliometric insights into transforming the management of rheumatoid arthritis: three decades of progress against opportunistic infections.
    Clin Exp Rheumatol. 2025 Jul 22. doi: 10.55563.
    PubMed     Abstract available
    
    
    
42. CHEN PK, Chen YM, Cho CF, Chen JJJW, et al
    A panel incorporating genetic variants of RIN3, NLRC3, and SLX4 shows promise in predicting remission after tofacitinib therapy in rheumatoid arthritis patients.
    Clin Exp Rheumatol. 2025 Jul 21. doi: 10.55563.
    PubMed     Abstract available
    
    
    June 2025
43. ZHENG Z, Liu X, Zhang Y, Zhang H, et al
    Research trends and hotspots on gut microbiota in rheumatoid arthritis: a bibliometric analysis from 2004 to 2024.
    Clin Exp Rheumatol. 2025 Jun 5. doi: 10.55563/clinexprheumatol/3899.
    PubMed     Abstract available
    
    
    May 2025
44. OKANO T, Di Carlo M, Salaffi F, Filippucci E, et al
    Peritenon extensor tendon inflammation at metacarpophalangeal joints level: a valuable ultrasound finding in the differential diagnosis between psoriatic arthritis and rheumatoid arthritis?
    Clin Exp Rheumatol. 2025 May 31. doi: 10.55563.
    PubMed     Abstract available
    
    
    
45. LI C, Zong S
    A comprehensive analysis of trends and inequalities in rheumatoid arthritis burden among women of childbearing age: insights from the Global Burden of Disease study 2021.
    Clin Exp Rheumatol. 2025 May 8. doi: 10.55563.
    PubMed     Abstract available
    
    
    
46. KATSOULI O, Orfanos P, Lainis V, Katsouli P, et al
    Drug survival and predictor factors for discontinuation of first-line biologic therapy in rheumatoid arthritis: data from a real-world single-centre study.
    Clin Exp Rheumatol. 2025 May 8. doi: 10.55563.
    PubMed     Abstract available
    
    
    
47. SONG Y, Ma J, Chu T, Wu M, et al
    Application of vascular index based on superb microvascular imaging technique for assessing disease activity in rheumatoid arthritis patients with signal-positive joints.
    Clin Exp Rheumatol. 2025 May 1. doi: 10.55563.
    PubMed     Abstract available
    
    
    
48. ROSSI A, Ferrari G, Galli V, Bonacini M, et al
    Immunomodulatory effects of dental pulp stem cells on lymphocytes and monocytes from patients with rheumatoid arthritis.
    Clin Exp Rheumatol. 2025;43:809-814.
    PubMed     Abstract available
    
    
    April 2025
49. OUDART F, Thomas M, Combier A, Molto A, et al
    Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice.
    Clin Exp Rheumatol. 2025 Apr 29. doi: 10.55563.
    PubMed     Abstract available
    
    
    
50. KIM JW, Lee SK, Shin K, Jung JY, et al
    Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents.
    Clin Exp Rheumatol. 2025 Apr 18. doi: 10.55563/clinexprheumatol/z9894.
    PubMed     Abstract available
    
    
    
51. DE MALEPRADE B, Gerard B, Brevet P, Riou G, et al
    Macrophage requirements for abatacept response in rheumatoid arthritis.
    Clin Exp Rheumatol. 2025 Apr 9. doi: 10.55563.
    PubMed     Abstract available
    
    
    March 2025
52. WANG X, He J, Zhong J, He J, et al
    Hydroxychloroquine inhibits the PI3K/AKT pathway in synovial fibroblasts of rheumatoid arthritis and alleviates collagen-induced arthritis in mice.
    Clin Exp Rheumatol. 2025 Mar 28. doi: 10.55563.
    PubMed     Abstract available
    
    
    
53. PENDOLINO M, Serban T, Ferrari G, Diana P, et al
    STEp-down approach in MEthotrexate use for the Treatment of Rheumatoid Arthritis (STEMETRA): a pilot study demonstrating efficacy and safety of short-term, high dose methotrexate.
    Clin Exp Rheumatol. 2025 Mar 20. doi: 10.55563.
    PubMed     Abstract available
    
    
    
54. WU YK, Zhou L, Chang G, Wang RQ, et al
    Identification and validation of fibroblast-related biomarkers in rheumatoid arthritis by bulk RNA-seq and single-cell RNA-seq analysis.
    Clin Exp Rheumatol. 2025 Mar 20. doi: 10.55563.
    PubMed     Abstract available
    
    
    
55. CHO MR, Kim YE, Lee YJ, Ahn SM, et al
    Risk of cervical intraepithelial neoplasia during Janus kinase inhibitor treatment in patients with rheumatoid arthritis: a retrospective cohort study.
    Clin Exp Rheumatol. 2025 Mar 13. doi: 10.55563.
    PubMed    
    
    
    
56. CHEN LF, Lin TM, Chang YS, Hsu HC, et al
    Effect of TNF-alpha blockers on reducing the risk of dementia in rheumatoid arthritis: a nationwide cohort study.
    Clin Exp Rheumatol. 2025 Mar 13. doi: 10.55563.
    PubMed     Abstract available
    
    
    
57. YU M, Wu J, Zhang S, Yan W, et al
    RBM15, an m6A enzyme, suppresses NLRP3 inflammasome activation in rheumatoid arthritis through macrophage metabolism.
    Clin Exp Rheumatol. 2025 Mar 5. doi: 10.55563.
    PubMed     Abstract available
    
    
    
58. CHENG S, Xu K, Hou W, Qin X, et al
    Integrated analysis of genome-wide copy number variation and exome-wide rare variation identified novel loci for rheumatoid arthritis.
    Clin Exp Rheumatol. 2025;43:459-466.
    PubMed     Abstract available
    
    
    February 2025
59. ZHOU Q, Zhu S, Dai S, Wu Q, et al
    Comparison of the efficacy of Janus kinase inhibitors and adalimumab in rheumatoid arthritis: a meta-analysis.
    Clin Exp Rheumatol. 2025 Feb 13. doi: 10.55563.
    PubMed     Abstract available
    
    
    
60. TIAN Y, Jin M, Li H, Li D, et al
    Advancements in rheumatoid arthritis immunotherapy: a comprehensive bibliometric analysis of research trends and hotspots (2003-2023).
    Clin Exp Rheumatol. 2025 Feb 11. doi: 10.55563.
    PubMed     Abstract available
    
    
    
61. NAMAS RA, El-Kaissi M, Memisoglu E, Khan S, et al
    Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and mortality in a large single-centre cohort.
    Clin Exp Rheumatol. 2025 Feb 11. doi: 10.55563.
    PubMed     Abstract available
    
    
    January 2025
62. AKASAKI Y, Yamada H, Kondo M, Fukushi JI, et al
    Cluster analysis identifies the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis: the FRANK registry.
    Clin Exp Rheumatol. 2025 Jan 14. doi: 10.55563.
    PubMed     Abstract available
    
    
    
63. HAGEGE O, Brevet P, Gerard B, Duhamel E, et al
    Evaluation of the nocebo effect after switching from etanercept or adalimumab originator to a biosimilar: a retrospective study of patients with inflammatory rheumatism.
    Clin Exp Rheumatol. 2025;43:87-95.
    PubMed     Abstract available
    
    
    December 2024
64. ZHANG G, Yao L, Zhu Q, Herrmann M, et al
    Cross-reactivity of anti-modified protein antibodies in rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Dec 20. doi: 10.55563.
    PubMed     Abstract available
    
    
    
65. SUZUKI K, Akiyama M, Kaneko Y
    Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review.
    Clin Exp Rheumatol. 2024 Dec 20. doi: 10.55563.
    PubMed     Abstract available
    
    
    
66. WU J, Li D
    Pilocarpine treatment of Sjogren's syndrome curative effect of meta-analysis of randomised controlled trials.
    Clin Exp Rheumatol. 2024;42:2490-2498.
    PubMed     Abstract available
    
    
    
67. LIU S, Chen C, Zheng Q, Sun H, et al
    Non-negligible prevalence of focal lymphocytic sialadenitis in minor salivary glands of non-Sjogren's disease individuals.
    Clin Exp Rheumatol. 2024;42:2499-2506.
    PubMed     Abstract available
    
    
    
68. SLUIJPERS NRF, Fadhil M, Stel AJ, Dijkstra PU, et al
    Reliability of colour Doppler ultrasonography of the major salivary glands in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2476-2482.
    PubMed     Abstract available
    
    
    
69. BANDEIRA M, Fisher BA
    The effect of smoking on Sjogren's disease development and severity: a comprehensive literature review.
    Clin Exp Rheumatol. 2024;42:2346-2356.
    PubMed     Abstract available
    
    
    
70. STANO S, Cacciapaglia F, Rinaldi A, Giannotta M, et al
    Anti-aquaporin-5 and anti-poly-U-binding-factor-60kDa protein antibodies in primary Sjogren's disease patients: preliminary data and correlation with disease activity indices.
    Clin Exp Rheumatol. 2024;42:2420-2426.
    PubMed     Abstract available
    
    
    
71. NAKSHBANDI U, Liefers SC, Arends S, Spijkervet FKL, et al
    Abatacept use for 24 weeks has a limited effect on salivary gland inflammation in Sjogren's disease patients.
    Clin Exp Rheumatol. 2024;42:2362-2368.
    PubMed     Abstract available
    
    
    
72. TROMBY F, Manfre V, Chatzis LG, Arends S, et al
    Clinical manifestations, imaging and treatment of Sjogren's disease: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:2322-2335.
    PubMed     Abstract available
    
    
    
73. GIOVANNINI I, De Martino M, Manfre V, Lorenzon M, et al
    Ultrasonographic scores and parotid histopathology in Sjogren's disease: challenges in lymphoma identification.
    Clin Exp Rheumatol. 2024;42:2483-2489.
    PubMed     Abstract available
    
    
    
74. AUSMA NS, van der Kraan YM, de Wolff L, Kokol H, et al
    Field testing and clinical validation of the mSQUASH to measure physical activity in patients with Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2468-2475.
    PubMed     Abstract available
    
    
    
75. BALDINI C, Chatzis LG, Fulvio G, La Rocca G, et al
    Pathogenesis of Sjogren's disease: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:2336-2343.
    PubMed     Abstract available
    
    
    
76. DE MARCHI G, Nano A, Fulvio G, Manfre V, et al
    Sjogren's disease and systemic lupus erythematosus overlap syndrome as distinct entity at crossroads of two autoimmune disorders: clinical characterisation from two Italian reference centres for both the diseases.
    Clin Exp Rheumatol. 2024;42:2453-2458.
    PubMed     Abstract available
    
    
    
77. CHATZIS LG, Goules AV, Baldini C, Pezoulas VC, et al
    The clinical phenotype of isolated ocular or oral dryness in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2507-2512.
    PubMed     Abstract available
    
    
    
78. TSAI HC, Liao HT, Chen WS, Lai CC, et al
    Reduced Deltex1 expression in T cells indicates increased disease activity in Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2459-2467.
    PubMed     Abstract available
    
    
    
79. PALLA P, Chatzis LG, Sipsas NV, Goules AV, et al
    Infections in Sjogren's disease: a clinical concern or not?
    Clin Exp Rheumatol. 2024;42:2531-2541.
    PubMed     Abstract available
    
    
    
80. MEINECKE A, Kreis K, Olson P, Hoeper JR, et al
    Impact of time to diagnosis in patients with primary Sjogren's syndrome: a cross-sectional study.
    Clin Exp Rheumatol. 2024;42:2444-2452.
    PubMed     Abstract available
    
    
    
81. HA YJ, Lee JI, Choi SR, Kang EH, et al
    Implications of thyroid-related autoantibodies in patients with Sjogren's syndrome without overt thyroid diseases.
    Clin Exp Rheumatol. 2024;42:2404-2411.
    PubMed     Abstract available
    
    
    
82. LIU Q, Xing X, He J
    Tofacitinib alleviated salivary gland inflammation and reduced the percentages of effector T cells in murine Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2437-2443.
    PubMed     Abstract available
    
    
    
83. LI X, Zhang S, Cheng T, Wang J, et al
    The abnormal expression of peripheral blood CD4+ T lymphocyte subsets are correlated with primary Sjogren's syndrome complicated with haematological involvement.
    Clin Exp Rheumatol. 2024;42:2412-2419.
    PubMed     Abstract available
    
    
    
84. D'AGOSTINO GENNARI J, Deveza GBH, Ribeiro CT, Seguro AC, et al
    Efficacy of N-acetylcysteine for treating dryness symptoms of Sjogren's disease: randomised placebo-controlled double-blind clinical study.
    Clin Exp Rheumatol. 2024;42:2427-2436.
    PubMed     Abstract available
    
    
    
85. KIM SH, Min HK
    Clinical utility of salivary and lacrimal gland ultrasonography in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2520-2530.
    PubMed     Abstract available
    
    
    
86. LONGHINO S, Treppo E, Manfre V, De Martino M, et al
    The impact of two different rituximab-based strategies in cryoglobulinaemic vasculitis secondary to Sjogren's disease: a monocentric cohort study.
    Clin Exp Rheumatol. 2024;42:2387-2392.
    PubMed     Abstract available
    
    
    
87. DENG C, Wang A, Li W, Chen Y, et al
    The role of imbalanced CD226/TIGIT on activated peripheral double-negative T cells in the pathogenesis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2369-2377.
    PubMed     Abstract available
    
    
    
88. CHEN W, Chen W, Xia N, Yan R, et al
    Investigation of pyroptosis-related hub genes and the immune microenvironment in primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2393-2403.
    PubMed     Abstract available
    
    
    
89. KOMORI K, Komori M, Horino T, Nishiyama S, et al
    Influence of doctor-patient relationships and health-related factors on the medical satisfaction of patients with Sjogren's disease.
    Clin Exp Rheumatol. 2024;42:2378-2386.
    PubMed     Abstract available
    
    
    
90. SONG Y, Zhou W
    Role of TLR7 in the pathogenesis of primary Sjogren's syndrome.
    Clin Exp Rheumatol. 2024;42:2513-2519.
    PubMed     Abstract available
    
    
    November 2024
91. VAN GEEL EH, Boers M, Hartman L, Smulders YM, et al
    Does high hepatic bioavailability enhance the effect of oral compared to subcutaneous glucocorticoids?
    Clin Exp Rheumatol. 2024;42:2265-2267.
    PubMed     Abstract available
    
    
    
92. WANG K, Jiang Y, Zhai J, Zhang P, et al
    WNT16 as a promising biomarker for systemic lupus erythematosus and its role in regulating cell proliferation and apoptosis.
    Clin Exp Rheumatol. 2024;42:2206-2214.
    PubMed     Abstract available
    
    
    
93. SON Y, Korenfeld D, Suarez-Fueyo A, Ruzek M, et al
    Understanding mechanisms of JAK1 inhibition on synovial fibroblasts using combinatorial approaches of bulk and single cell RNAseq analyses.
    Clin Exp Rheumatol. 2024;42:2194-2205.
    PubMed     Abstract available
    
    
    October 2024
94. RUYSSEN-WITRAND A, Dimeglio C, Nogue E, Molinary N, et al
    Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts.
    Clin Exp Rheumatol. 2024 Oct 17. doi: 10.55563/clinexprheumatol/48440.
    PubMed     Abstract available
    
    
    
95. VAN COMPERNOLLE K, Selleslag D, Hazlewood GS, Storek J, et al
    Allogeneic stem cell transplantation in difficult-to-treat rheumatoid arthritis.
    Clin Exp Rheumatol. 2024 Oct 17. doi: 10.55563.
    PubMed    
    
    
    
96. LA FERRARA R, Lazzaro FG, Alonzi G, Fiore S, et al
    Ultrasound versus clinical remission in patients with early rheumatoid arthritis: concordance and relationship with therapy discontinuation.
    Clin Exp Rheumatol. 2024 Oct 15. doi: 10.55563.
    PubMed     Abstract available
    
    
    
97. FOURNIER J, Boussat B, Dervaux B, Gaudin P, et al
    Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis.
    Clin Exp Rheumatol. 2024 Oct 3. doi: 10.55563.
    PubMed     Abstract available
    
    
    
98. OKA H, Sumitomo S, Shimizu H, Ohmura K, et al
    Markedly elevated serum IL-6 levels predict relapse within six months of treatment initiation in Still's disease.
    Clin Exp Rheumatol. 2024;42:2100-2101.
    PubMed    
    
    
    September 2024
99. D'ORAZIO A, Cirillo AL, Greco G, Di Ruscio E, et al
    Pathogenesis of rheumatoid arthritis: one year in review 2024.
    Clin Exp Rheumatol. 2024;42:1707-1713.
    PubMed     Abstract available
    
    
    
100. HAN M, Ha JW, Jung I, Kim CY, et al
     Association between Mycobacterium tuberculosis infection and the risk of inflammatory arthritides.
     Clin Exp Rheumatol. 2024;42:1812-1819.
     PubMed     Abstract available
     
     
     August 2024
101. QIAN Y, Zhang B, Nian F
     The association between rheumatoid arthritis and left ventricular diastolic dysfunction: pathogenesis, predictors and managements.
     Clin Exp Rheumatol. 2024 Aug 20. doi: 10.55563.
     PubMed     Abstract available
     
     
     
102. MIN HK, Lee JY, Lee SH, Ju JH, et al
     Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors.
     Clin Exp Rheumatol. 2024 Aug 8. doi: 10.55563.
     PubMed     Abstract available
     
     
     July 2024
103. MIN HK, Lee JY, Lee SH, Kim HR, et al
     Interleukin-18 binding protein regulates mast cell activation and mast cell induced osteoclastogenesis of rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Jul 25. doi: 10.55563.
     PubMed     Abstract available
     
     
     
104. WIENTJES MHM, van Huissteden J, van Herwaarden N, Verhoef LM, et al
     Dose reduction of rituximab in clinical practice: a retrospective cohort study of rheumatoid arthritis patients in low disease activity on rituximab.
     Clin Exp Rheumatol. 2024 Jul 24. doi: 10.55563.
     PubMed     Abstract available
     
     
     
105. ZHANG Y, Shi J, Xie Y, Shao H, et al
     Exploring the supplementary potential of all-trans retinoic acid with methotrexate in rheumatoid arthritis: modulation of synovial cell apoptosis and autophagy.
     Clin Exp Rheumatol. 2024 Jul 8. doi: 10.55563.
     PubMed     Abstract available
     
     
     
106. OTA T, Ota SI
     Impact of anti-human IgG hinge peptide antibodies on identification of patients with early seronegative rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Jul 5. doi: 10.55563.
     PubMed     Abstract available
     
     
     
107. RUZZON F, Adami G
     Environment and arthritis.
     Clin Exp Rheumatol. 2024;42:1343-1349.
     PubMed     Abstract available
     
     
     
108. MONTAGNON PY, Beauger M, Couderc M, Tournadre A, et al
     Haptoglobin blood assay to assess treatment compliance in rheumatoid arthitis patients treated with tocilizumab.
     Clin Exp Rheumatol. 2024;42:1516.
     PubMed    
     
     
     
109. VIVEIROS L, Neves A, Gouveia T, Isenberg DA, et al
     A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients.
     Clin Exp Rheumatol. 2024;42:1480-1486.
     PubMed     Abstract available
     
     
     June 2024
110. MOVAHEDI M, Choquette D, Coupal L, Keystone E, et al
     Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data.
     Clin Exp Rheumatol. 2024 Jun 6. doi: 10.55563.
     PubMed     Abstract available
     
     
     
111. LIU X, Wu L, Chen S, Liang X, et al
     Group 3 innate lymphoid cells promotes Th17 cells differentiation in rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Jun 6. doi: 10.55563.
     PubMed     Abstract available
     
     
     
112. MAIOLI G, Cincinelli G, Biggioggero M, Caporali R, et al
     The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience.
     Clin Exp Rheumatol. 2024 Jun 4. doi: 10.55563.
     PubMed     Abstract available
     
     
     May 2024
113. KANG T, Xi Y, Qian T, Lu S, et al
     Exploring the link between dietary omega-3 and omega-6 fatty acid intake and rheumatoid arthritis risk: NHANES 1999-2020 study.
     Clin Exp Rheumatol. 2024 May 6. doi: 10.55563.
     PubMed     Abstract available
     
     
     
114. CICIRIELLO S, Littlejohn GO, Treuer T, Gibson KA, et al
     Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.
     Clin Exp Rheumatol. 2024 May 1. doi: 10.55563.
     PubMed     Abstract available
     
     
     
115. MOLTENI E, Adinolfi A, Bondi V, Delvino P, et al
     Novel insights into the management of rheumatoid arthritis: one year in review 2024.
     Clin Exp Rheumatol. 2024;42:947-960.
     PubMed     Abstract available
     
     
     
116. SHU CC, Chen PS, Lin ZH, Hsiao CT, et al
     Prevalence and risk factors of non-tuberculous mycobacterial pulmonary isolates and infection in interstitial lung disease associated with systemic autoimmune disease.
     Clin Exp Rheumatol. 2024;42:1006-1014.
     PubMed     Abstract available
     
     
     
117. CHEN HW, Huang CH, Huang CF, Chang CH, et al
     Distinct subsets of synovial fibroblasts control cartilage destruction in joint diseases.
     Clin Exp Rheumatol. 2024;42:1118-1126.
     PubMed     Abstract available
     
     
     April 2024
118. FORNARO M, Caporali R, Biggioggero M, Bugatti S, et al
     Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.
     Clin Exp Rheumatol. 2024 Apr 17. doi: 10.55563.
     PubMed     Abstract available
     
     
     
119. KIM JW, Shin K, Jung J, Suh CH, et al
     Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry.
     Clin Exp Rheumatol. 2024 Apr 16. doi: 10.55563.
     PubMed     Abstract available
     
     
     
120. KONG X, Wang W
     Association between Life's Essential 8 and all-cause or cardiovascular-specific mortality in patients with rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Apr 5. doi: 10.55563.
     PubMed     Abstract available
     
     
     March 2024
121. GILDEMEISTER N, Redeker I, Buehring B, Andreica I, et al
     Prevalence of remission in patients with rheumatoid arthritis in daily clinical practice: long-term data from a tertiary care centre.
     Clin Exp Rheumatol. 2024 Mar 26. doi: 10.55563.
     PubMed     Abstract available
     
     
     
122. SEBASTIANI M, Zabotti A, Biasi B, Cacioppo S, et al
     Factors associated of long-term retention rate of Janus kinase inhibitors in a multi-failure rheumatoid arthritis population.
     Clin Exp Rheumatol. 2024 Mar 26. doi: 10.55563.
     PubMed     Abstract available
     
     
     
123. KANNAYIRAM S, Schmukler J, Li T, Goodson N, et al
     Elevated DAS28-ESR in patients with rheumatoid arthritis who have comorbid fibromyalgia is associated more with tender joint counts than with patient global assessment or swollen joint counts: implications for assessment of inflammatory activity.
     Clin Exp Rheumatol. 2024 Mar 22. doi: 10.55563.
     PubMed     Abstract available
     
     
     
124. LEBEL N, Marie I, Grosjean J, Brevet P, et al
     Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases.
     Clin Exp Rheumatol. 2024.
     PubMed     Abstract available
     
     
     
125. FLIPO RM, Constantin A, Goupille P, Chartier M, et al
     Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study.
     Clin Exp Rheumatol. 2024 Mar 3. doi: 10.55563.
     PubMed     Abstract available
     
     
     
126. WU Y, Li X, Ke J, Zhang B, et al
     Increased expression of omentin-1 is associated with synovitis and bone destruction in rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Mar 3. doi: 10.55563.
     PubMed     Abstract available
     
     
     
127. KUMARADEV S, Roux C, Sellam J, Perrot S, et al
     Do subjective components of disease activity contribute to heterogeneity in opioid prescriptions in inflammatory rheumatic diseases? Results from ESPOIR and DESIR cohorts.
     Clin Exp Rheumatol. 2024;42:671-681.
     PubMed     Abstract available
     
     
     February 2024
128. KHULLAR A, Dhir V, Saikia B, Yadav AK, et al
     Rheumatoid arthritis synovial fluid shows enrichment of T-cells producing GMCSF which are polyfunctional for TNFalpha and IFNgamma.
     Clin Exp Rheumatol. 2024 Feb 12. doi: 10.55563.
     PubMed     Abstract available
     
     
     
129. CEN X, Chen Y, Liu H, Luo Y, et al
     Methotrexate inhibits LPS-induced glycolysis in fibroblast-like synoviocytes isolated from patients with rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Feb 6. doi: 10.55563.
     PubMed    
     
     
     
130. FEDERICO JA, Syvaranta SA, Tuohinen SS, Holmstrom MM, et al
     Myocardial T1 mapping by cardiac magnetic resonance imaging shows early myocardial changes in treatment-naive patients with active rheumatoid arthritis and positive autoantibodies.
     Clin Exp Rheumatol. 2024 Feb 6. doi: 10.55563.
     PubMed     Abstract available
     
     
     January 2024
131. ALP G, Cinakli H, Kurut Aysin I, Solmaz D, et al
     Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.
     Clin Exp Rheumatol. 2024 Jan 31. doi: 10.55563.
     PubMed     Abstract available
     
     
     
132. GUO N, Li X, Movahedi M, Cesta A, et al
     Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry.
     Clin Exp Rheumatol. 2024 Jan 31. doi: 10.55563.
     PubMed     Abstract available
     
     
     
133. LA BARBERA L, Rizzo C, Camarda F, Atzeni F, et al
     Effectiveness and safety of filgotinib in rheumatoid arthritis: a real-life multicentre experience.
     Clin Exp Rheumatol. 2024 Jan 8. doi: 10.55563.
     PubMed     Abstract available
     
     
     
134. MARTINEZ-FEITO A, Plasencia-Rodriguez C, Novella-Navarro M, Gehin JE, et al
     Influence of rheumatoid factor on serum drug levels of tumour necrosis factor inhibitors with different structures in rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Jan 8. doi: 10.55563.
     PubMed     Abstract available
     
     
     
135. CHEN CH, Liao HT, Chen HA, Yen YN, et al
     Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis.
     Clin Exp Rheumatol. 2024 Jan 5. doi: 10.55563.
     PubMed     Abstract available
     
     
     
136. SHI L, Yang J, Xu J, Dai J, et al
     Elevated serum soluble CD27 levels are associated with both disease activity and humoral immune activity in patients with rheumatoid arthritis.
     Clin Exp Rheumatol. 2024 Jan 2. doi: 10.55563.
     PubMed     Abstract available
     
     
     
137. DOBIES B, White AJ, Isberg A, Gudmundsson SF, et al
     Digital health program improves quality of life in rheumatoid arthritis: a retrospective analysis of real-world data.
     Clin Exp Rheumatol. 2024;42:10-14.
     PubMed     Abstract available
     
     
     December 2023
138. TAN YK, Lim GH
     Assessment of joint inflammation at the wrist of patients with rheumatoid arthritis: thermography findings closely mirror those from ultrasonography.
     Clin Exp Rheumatol. 2023 Dec 7. doi: 10.55563.
     PubMed     Abstract available
     
     
     
139. HOFSTEDT O, Wahlin B, Sodergren A
     Associations between serological biomarkers and subclinical atherosclerosis in patients with rheumatoid arthritis after 11 years of follow-up.
     Clin Exp Rheumatol. 2023 Dec 4. doi: 10.55563.
     PubMed     Abstract available
     
     
     
140. FULVIO G, La Rocca G, Chatzis LG, Ferro F, et al
     Impact of gender and age at onset on Sjogren's syndrome presentation and outcome: state of the art.
     Clin Exp Rheumatol. 2023;41:2547-2554.
     PubMed     Abstract available
     
     
     
141. TOMIZAWA T, Cox T, Kollert F, Bowman SJ, et al
     The impact of concomitant Sjogren's disease on rheumatoid arthritis disease activity: a systematic review and meta-analysis.
     Clin Exp Rheumatol. 2023;41:2484-2492.
     PubMed     Abstract available
     
     
     
142. LONGHINO S, Chatzis LG, Dal Pozzolo R, Peretti S, et al
     Sjogren's syndrome: one year in review 2023.
     Clin Exp Rheumatol. 2023;41:2343-2356.
     PubMed     Abstract available
     
     
     
143. COLAFRANCESCO S, Simoncelli E, Priori R, Bombardieri M, et al
     The pathogenic role of metabolism in Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2538-2546.
     PubMed     Abstract available
     
     
     
144. MANFRE V, Parisi S, Caligiuri I, Repetto O, et al
     Secretagogue effect of PDE4 inhibitor apremilast on human salivary gland organoids obtained from primary Sjogren's syndrome patients.
     Clin Exp Rheumatol. 2023;41:2493-2501.
     PubMed     Abstract available
     
     
     
145. JIANG T, Guo J, Wang Y, Wu H, et al
     Total glucosides of paeony alleviates experimental Sjogren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells.
     Clin Exp Rheumatol. 2023;41:2502-2510.
     PubMed     Abstract available
     
     
     
146. BALDINI C, La Rocca G, Fulvio G, Grossi E, et al
     Artificial neural network and deep learning in Sjogren's disease: where we are and where we are going.
     Clin Exp Rheumatol. 2023;41:2360-2362.
     PubMed    
     
     
     
147. COLAFRANCESCO S, Celia AI, Baldini C, Quartuccio L, et al
     Clinical and histological features of patients with primary Sjogren's syndrome and autoimmune thyroiditis: a national multicentre cross-sectional study.
     Clin Exp Rheumatol. 2023;41:2389-2396.
     PubMed     Abstract available
     
     
     
148. SLUIJPERS NRF, Delli K, De Wolff L, Stel AJ, et al
     Longitudinal evaluation of major salivary gland functioning in Sjogren's disease patients in a prospective standard-of-care cohort.
     Clin Exp Rheumatol. 2023;41:2474-2483.
     PubMed     Abstract available
     
     
     
149. DELLI K, Van Nimwegen JF, Arends S, Stel AJ, et al
     Can ultrasound of the major salivary glands differentiate Sjogren's disease from its major mimics?
     Clin Exp Rheumatol. 2023;41:2467-2473.
     PubMed     Abstract available
     
     
     
150. VAN SANTEN JS, Assy Z, Bikker FJ, Laine ML, et al
     The diagnostic power of salivary electrolytes for Sjogren's disease: a systematic literature review and meta-analysis.
     Clin Exp Rheumatol. 2023;41:2511-2524.
     PubMed     Abstract available
     
     
     
151. ZABOTTI A, Giovannini I, Longhino S, Manfre V, et al
     Nuts and bolts of salivary gland pathology in primary Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2525-2537.
     PubMed     Abstract available
     
     
     
152. MARTINEZ-NAVA GA, Lopez-Reyes A, Hernandez-Hernandez C, Ruiz-Gonzalez V, et al
     Characterisation of crevicular fluid microbiota in primary Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2458-2466.
     PubMed     Abstract available
     
     
     
153. GROOTELAAR RGJ, van Ginkel MS, Nienhuis PH, Arends S, et al
     Salivary gland 18F-FDG-PET/CT uptake patterns in Sjogren's syndrome and giant cell arteritis patients.
     Clin Exp Rheumatol. 2023;41:2428-2436.
     PubMed     Abstract available
     
     
     
154. BARTOLONI E, Perricone C, Cafaro G, Gerli R, et al
     Cardiovascular risk in patients with Sjogren's syndrome: is it time for a new approach?
     Clin Exp Rheumatol. 2023;41:2357-2359.
     PubMed    
     
     
     
155. FLORES-CHAVEZ A, Brito-Zeron P, Ng WF, Szanto A, et al
     Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2437-2447.
     PubMed     Abstract available
     
     
     
156. BRITO-ZERON P, Flores-Chavez A, Ng WF, Fanny Horvath I, et al
     Exposure to air pollution as an environmental determinant of how Sjogren's disease is expressed at diagnosis.
     Clin Exp Rheumatol. 2023;41:2448-2457.
     PubMed     Abstract available
     
     
     
157. YANG J, Xu J
     Autologous haematopoietic stem cell transplantation for primary Sjogren's syndrome with severe refractory thrombocytopenia: a case report.
     Clin Exp Rheumatol. 2023;41:2557-2558.
     PubMed    
     
     
     
158. AKIYAMA M, Yoshimoto K, Kaneko Y
     Significant association of CX3CR1+CD8 T cells with aging and distinct clinical features in Sjogren's syndrome and IgG4-related disease.
     Clin Exp Rheumatol. 2023;41:2409-2417.
     PubMed     Abstract available
     
     
     
159. BARRIO-CORTES J, Gomez-Gascon T, Benito-Sanchez B, Dominguez-Berjon MF, et al
     Utilisation of primary healthcare services by Sjogren's syndrome patients in the Community of Madrid and associated factors: a population-based cross-sectional study.
     Clin Exp Rheumatol. 2023;41:2397-2408.
     PubMed     Abstract available
     
     
     
160. ANTOINE P, Morell-Dubois S, Maillard H, Wojtasik G, et al
     Six medico-psycho-social dimensions of a pedagogical model used to define clusters of patients with Sjogren's syndrome and intentionality to participate in a patient education programme.
     Clin Exp Rheumatol. 2023;41:2379-2388.
     PubMed     Abstract available
     
     
     
161. LIU Y, Guo L, Lin W, Ning X, et al
     Anticentromere antibody positive patients with primary Sjogren's syndrome have distinctive clinical and immunological characteristics.
     Clin Exp Rheumatol. 2023;41:2371-2378.
     PubMed     Abstract available
     
     
     
162. CRUZ-BAUTISTA I, Almeda-Valdes P, Lopez-Carrasco G, Antonio-Villa N, et al
     High levels of rheumatoid factor: association with thyroid antibodies and other analytical thyroid interferences in Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2555-2556.
     PubMed    
     
     
     
163. PARK Y, Lee JJ, Koh JH, Kim MJ, et al
     Kynurenine pathway can be a potential biomarker of fatigue in primary Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41:2363-2370.
     PubMed     Abstract available
     
     
     November 2023
164. QI W, Li F, Wang G, Yan Y, et al
     The effects of mesenchymal stem cells-derived exosomes in rheumatoid arthritis: a review.
     Clin Exp Rheumatol. 2023 Nov 23. doi: 10.55563.
     PubMed     Abstract available
     
     
     
165. GOVONI M, Batalov A, Boumpas DT, D'Angelo S, et al
     Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-alpha inhibitor therapy: a pooled analysis of European prospective observationa
     Clin Exp Rheumatol. 2023 Nov 15. doi: 10.55563.
     PubMed     Abstract available
     
     
     
166. WITTE T, Kiltz U, Haas F, Riechers E, et al
     The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.
     Clin Exp Rheumatol. 2023 Nov 15. doi: 10.55563/clinexprheumatol/11255.
     PubMed     Abstract available
     
     
     October 2023
167. FORSS A, Sotoodeh A, van Vollenhoven RF, Ludvigsson JF, et al
     Prevalence of coeliac disease in patients with rheumatoid arthritis and juvenile idiopathic arthritis: a systematic review and meta-analysis.
     Clin Exp Rheumatol. 2023 Oct 25. doi: 10.55563.
     PubMed     Abstract available
     
     
     
168. LI S, Shi Y, Fang W, Feng Y, et al
     A bidirectional Mendelian randomisation study of the association between rheumatoid arthritis and frailty.
     Clin Exp Rheumatol. 2023 Oct 25. doi: 10.55563.
     PubMed     Abstract available
     
     
     
169. AMMITZBOLL C, Thomsen MK, Andersen JB, Jensen JMB, et al
     Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
     Clin Exp Rheumatol. 2023 Oct 23. doi: 10.55563.
     PubMed     Abstract available
     
     
     
170. CORDEIRO RA, Antonelli IPB, Giardini HAM
     Adult-onset Still's disease with ankylosis of the distal interphalangeal joints: beyond psoriatic arthritis.
     Clin Exp Rheumatol. 2023;41:2126-2127.
     PubMed    
     
     
     
171. LIN YH, Chang SH, Hsu TC, Chen PK, et al
     Elevated monocyte distribution width in patients with active adult-onset Still's disease: a novel activity indicator.
     Clin Exp Rheumatol. 2023;41:2062-2070.
     PubMed     Abstract available
     
     
     September 2023
172. CAO S, Liu X, Li Y, Yang Y, et al
     Serum sCD25 is an indicator for rheumatoid arthritis-associated interstitial lung disease.
     Clin Exp Rheumatol. 2023 Sep 22. doi: 10.55563.
     PubMed     Abstract available
     
     
     
173. LO PIZZO M, La Barbera L, Rizzo C, Mohammadnezhad L, et al
     JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis.
     Clin Exp Rheumatol. 2023 Sep 21. doi: 10.55563.
     PubMed     Abstract available
     
     
     
174. GOU Y, Zhang J, Li C, Liu Y, et al
     Causal relationship between gut microbiota and rheumatoid arthritis: a two-sample Mendelian randomisation study.
     Clin Exp Rheumatol. 2023 Sep 15. doi: 10.55563.
     PubMed     Abstract available
     
     
     
175. PISANI F, Croia C, Petrelli F, Chericoni E, et al
     The multifaceted role of mast cells in the pathogenesis of rheumatoid arthritis.
     Clin Exp Rheumatol. 2023 Sep 7. doi: 10.55563.
     PubMed     Abstract available
     
     
     
176. MANZO C, Nune A, Castagna A
     Why would immuno- and endocrino-senescence, age-related changes in the gut microbiota, and susceptibility to infection favour polymyalgia rheumatica over seronegative elderly-onset rheumatoid arthritis?
     Clin Exp Rheumatol. 2023;41 Suppl 135:25-26.
     PubMed    
     
     
     
177. ABACAR KY, Aydin-Tatli I, Colakoglu S, Inanc N, et al
     Paraffin stimulation might not be necessary for the collection of saliva: effect on the rate and cellular distribution in primary Sjogren's syndrome.
     Clin Exp Rheumatol. 2023;41 Suppl 135:18-19.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum